TG THERAPEUTICS INC (TGTX) Stock Price, Quote, News and Overview
NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD
TGTX Quote, Performance and Key Statistics
NASDAQ:TGTX (8/13/2025, 1:43:55 PM)
27.83
+0.71 (+2.62%)
The current stock price of TGTX is 27.83 USD. In the past month the price decreased by -28.56%. In the past year, price increased by 22.83%.
TGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.99 | 355.24B | ||
| AMGN | AMGEN INC | 13.22 | 155.03B | ||
| GILD | GILEAD SCIENCES INC | 15.49 | 149.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.25 | 101.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.24 | 60.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.85B | ||
| ARGX | ARGENX SE - ADR | 69.49 | 39.43B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.62 | 32.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.12B | ||
| INSM | INSMED INC | N/A | 23.14B | ||
| NTRA | NATERA INC | N/A | 21.44B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.43B |
Related stock screener links
About TGTX
Company Profile
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 338 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Company Info
TG THERAPEUTICS INC
3020 Carrington Mill Blvd., Suite 475
Morrisville NORTH CAROLINA 10014 US
CEO: Michael S. Weiss
Employees: 338
Phone: 18775758489
TG THERAPEUTICS INC / TGTX FAQ
What is the stock price of TG THERAPEUTICS INC today?
The current stock price of TGTX is 27.83 USD. The price increased by 2.62% in the last trading session.
What is the ticker symbol for TG THERAPEUTICS INC stock?
The exchange symbol of TG THERAPEUTICS INC is TGTX and it is listed on the Nasdaq exchange.
On which exchange is TGTX stock listed?
TGTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TG THERAPEUTICS INC stock?
15 analysts have analysed TGTX and the average price target is 42.55 USD. This implies a price increase of 52.89% is expected in the next year compared to the current price of 27.83. Check the TG THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TG THERAPEUTICS INC worth?
TG THERAPEUTICS INC (TGTX) has a market capitalization of 4.42B USD. This makes TGTX a Mid Cap stock.
How many employees does TG THERAPEUTICS INC have?
TG THERAPEUTICS INC (TGTX) currently has 338 employees.
What are the support and resistance levels for TG THERAPEUTICS INC (TGTX) stock?
TG THERAPEUTICS INC (TGTX) has a support level at 26.71 and a resistance level at 33.5. Check the full technical report for a detailed analysis of TGTX support and resistance levels.
Is TG THERAPEUTICS INC (TGTX) expected to grow?
The Revenue of TG THERAPEUTICS INC (TGTX) is expected to grow by 85.34% in the next year. Check the estimates tab for more information on the TGTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TG THERAPEUTICS INC (TGTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TGTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TGTX, evaluating the profitability, health, valuation and growth aspects
- TG THERAPEUTICS INC (TGTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TG THERAPEUTICS INC (TGTX) Sales and EPS estimates to see what analysts future expectations are.
- TG THERAPEUTICS INC (TGTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TG THERAPEUTICS INC (TGTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TG THERAPEUTICS INC (TGTX) Stock Chart to make your own analysis
- TG THERAPEUTICS INC (TGTX) Latest news and press-releases to stay up to date.
Does TG THERAPEUTICS INC (TGTX) stock pay dividends?
TGTX does not pay a dividend.
When does TG THERAPEUTICS INC (TGTX) report earnings?
TG THERAPEUTICS INC (TGTX) will report earnings on 2025-11-03.
What is the Price/Earnings (PE) ratio of TG THERAPEUTICS INC (TGTX)?
The PE ratio for TG THERAPEUTICS INC (TGTX) is 75.22. This is based on the reported non-GAAP earnings per share of 0.37 and the current share price of 27.83 USD. Check the full fundamental report for a full analysis of the valuation metrics for TGTX.
What is the Short Interest ratio of TG THERAPEUTICS INC (TGTX) stock?
The outstanding short interest for TG THERAPEUTICS INC (TGTX) is 16.87% of its float. Check the ownership tab for more information on the TGTX short interest.
TGTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX turns out to be only a medium performer in the overall market: it outperformed 42.1% of all stocks.
TGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TGTX. While TGTX is still in line with the averages on profitability rating, there are concerns on its financial health.
TGTX Financial Highlights
Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of 0.37. The EPS decreased by -38.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.13% | ||
| ROA | 5.96% | ||
| ROE | 16.5% | ||
| Debt/Equity | 1.03 |
TGTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to TGTX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 467.07% and a revenue growth 85.34% for TGTX